All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2006-003147-23 | Estudio de Fase 2 abierto, multicentrico para evaluar la eficacia y tolerancia del IMC-11F8 en combinación con 5-FU/FA y Oxaliplatino (Folfox-6 modificado) en paciente con un cáncer colorectal no trat... | 2010-10-29 | due-trials |
| Not reported Terminated | 2007-006713-16 | Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma | 2008-10-27 | due-trials |
| Reported results | 2007-006715-22 | A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-small Cell Lung Cancer | 2011-10-04 | due-trials |
| Reported results | 2007-006717-17 | A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | 2012-04-25 | due-trials |
| Reported results | 2007-006719-21 | A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET | 2012-06-19 | due-trials |
| Reported results | 2008-001727-65 | A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Loc... | 2020-11-19 | due-trials |
| Reported results | 2008-004936-19 | "Estudio de fase 2, multicéntrico, en abierto, para evaluar la seguridad y la eficacia del IMC-1121B en combinación con 5-FU/AF y oxaliplatino (FOLFOX-6 modificado) como tratamiento de primera línea e... | 2011-08-22 | due-trials |
| Reported results | 2008-005964-15 | "Estudio de fase 3, aleatorizado y doble ciego de IMC-1121B y el mejor tratamiento complementario (MTC) en comparación con placebo y MTC en el tratamiento del adenocarcinoma metastásico gástrico o de ... | 2015-12-17 | due-trials |
| Reported results | 2009-009035-30 | Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractor... | 2012-05-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2009-012574-12 | "Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con pemetrexed-cisplatino más IMC-11F8 en comparación con quimioterapia con pemetrexed-cisplatino sola en el tratamiento de pr... | 2020-12-23 | bad-data |
| Listed as ongoing, but also has a completion date | 2009-013838-25 | "Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con gemcitabina-cisplatino más IMC-11F8 en comparación con quimioterapia con gemcitabina-cisplatino sola en el tratamiento de ... | 2024-05-03 | bad-data |
| Reported results | 2009-016784-11 | An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemother... | 2018-04-19 | due-trials |
| Reported results | 2009-018015-11 | "Estudio de fase 2, aleatorizado, de IMC-3G3, un anticuerpo monoclonal anti-PDGFRalfa humano, más mitoxantrona y prednisona frente a mitoxantrona más prednisona en el cáncer de próstata metastásico re... | 2013-10-01 | due-trials |
| Reported results | 2010-019318-26 | "Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, del Ramucirumab (IMC-1121B) y el mejor tratamiento de soporte (BSC) frente a placebo más el BSC como tratamiento de segunda línea en pacie... | 2015-03-17 | due-trials |
| Reported results | 2010-020426-18 | A Randomized, Multicenter, Double-Bind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, R... | 2017-02-20 | due-trials |
| Reported results | 2010-022560-12 | A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST) | 2012-12-19 | due-trials |